Rules for drug trials should be tightened, say expertsBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7562.276-a (Published 03 August 2006) Cite this as: BMJ 2006;333:276
- Zosia Kmietowicz
Experts have made a raft of recommendations about how early clinical studies of new drugs should be designed, to improve their safety for the people taking part.
An interim report from an expert scientific group chaired by Gordon Duff, professor of molecular medicine at Sheffield University and chairman of the government's Commission on Human Medicines, says that new high risk agents in phase I studies—the first time drugs are tested in humans—should be given to one …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial